Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | BPTF | Q12830 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL557175 | 0.97 | SLC18A3 (0.56) | SLC18A3SIGMAR1CHRNB4CHRNA3BPTF | |
| SCHEMBL14066566 | 0.90 | SLC18A3 (0.60) | SLC18A3SIGMAR1CHRNB4CHRNA3KMT2A | |
| SCHEMBL10505554 | 0.90 | SLC18A3 (0.54) | SLC18A3SIGMAR1CHRNB4CHRNA3GAA | |
| Hydrochloric Acid SCHEMBL10682352 | 0.87 | SLC18A3 (0.52) | SLC18A3SIGMAR1CHRNB4CHRNA3GAA | |
| SCHEMBL14704853 | 0.85 | SLC18A3 (0.50) | SLC18A3SIGMAR1CHRNB4CHRNA3BPTF | |
| SCHEMBL16608333 | 0.85 | SLC18A3 (0.50) | SLC18A3SIGMAR1CHRNB4CHRNA3BPTF | |
| SCHEMBL16608244 | 0.85 | SLC18A3 (0.50) | SLC18A3SIGMAR1CHRNB4CHRNA3BPTF | |
| SCHEMBL18722791 | 0.85 | SLC18A3 (0.50) | SLC18A3SIGMAR1CHRNB4CHRNA3BPTF | |
| SCHEMBL28162463 | 0.84 | SLC18A3 (0.54) | SLC18A3SIGMAR1CHRNB4CHRNA3KMT2A | |
| SCHEMBL18270879 | 0.83 | SLC18A3 (0.52) | SLC18A3SIGMAR1KDM1AMAOAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107735088-A | Histone deacetylase inhibitors, compositions and methods of use thereof | CHDI基金会股份有限公司 | 2018-02-23 | — | — | CN | claimed |
| EP-2367785-B1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-10-15 | — | — | EP | claimed |
| US-8586572-B2 | 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2013-11-19 | — | — | US | claimed |
| EP-2367786-B1 | NOVEL 1 -ALKYL- 3 -HYDROXY- 3 -PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2013-01-09 | — | — | EP | claimed |
| US-20110281835-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-11-17 | — | — | US | claimed |
| US-20110257148-A1 | NOVEL 1-ALKYL-3-HYDROXY-3-PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-10-20 | — | — | US | claimed |
| CN-102224135-A | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB | 2011-10-19 | — | — | CN | claimed |
| EP-2367785-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-09-28 | — | — | EP | claimed |
| EP-2367786-A1 | NOVEL 1 -ALKYL- 3 -HYDROXY- 3 -PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-09-28 | — | — | EP | claimed |
| WO-2010058020-A1 | NOVEL 1 -ALKYL- 3 -HYDROXY- 3 -PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-05-27 | — | — | WO | claimed |
| WO-2010058017-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-05-27 | — | — | WO | claimed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250346574-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-13 | — | — | US | disclosed |
| EP-1654249-A1 | ANTHELMINTIC AND INSECTICIDE PYRIMIDINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005108368-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005014573-A1 | ANTHELMINTIC AND INSECTICIDE PYRIMIDINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050032810-A1 | Novel anthelmintic and insecticidal compositions | PHARMACIA AND UPJOHN COMPANY | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | PIKFYVE, TARDBP, TDP1 | SLC18A3 474/4885SIGMAR1 4028/4885CHRNB4 1872/4885 |
| US-20050032810-A1 | Novel anthelmintic and insecticidal compositions | ACHE, DHX29, DHX35 | SLC18A3 1773/4885SIGMAR1 4091/4885CHRNB4 3437/4885 |
| US-20110281835-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | SLC6A2, SLC18A2, SLC6A3 | SLC18A3 6/4885SIGMAR1 241/4885CHRNB4 32/4885 |
| US-20250346574-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | RECQL, H1-5, H1-3 | SLC18A3 4249/4885SIGMAR1 3102/4885CHRNB4 4349/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | SLC18A3 4434/4885SIGMAR1 1539/4885CHRNB4 3743/4885 |
| US-20110257148-A1 | NOVEL 1-ALKYL-3-HYDROXY-3-PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | DBH, SLC6A3, ADRA2B | SLC18A3 48/4885SIGMAR1 55/4885CHRNB4 39/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | SLC18A3 4373/4885SIGMAR1 1652/4885CHRNB4 3709/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | SLC18A3 1274/4885SIGMAR1 2716/4885CHRNB4 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.